title: The importance of schedule in whole body thermochemotherapy.
abstract: OBJECTIVE
  To determine an effective triple-agent schedule combining fever-range whole body thermal therapy (FR-WB-TT) with cisplatin and gemcitabine by optimizing the timing of drug with heat, and drug with drug.
  
  
  METHODS
  Using an orthotopically implanted syngeneic breast adenocarcinoma in an immunologically normal female Fischer rat model, we investigated various schedules of a thermochemotherapy regimen combining FR-WB-TT with chemotherapy agents, cisplatin and gemcitabine. Differently timed combinations of a) cisplatin with FR-WB-TT, b) gemcitabine with FR-WB-TT, and c) cisplatin with gemcitabine were examined for anti-tumor efficacy and toxicity. A combination of the three agents based on the optimal two-agent schedules was then tested.
  
  
  RESULTS
  The greatest primary tumor and axillary metastasis growth delay and lowest toxicity was induced with administration of cisplatin 24 h prior to gemcitabine and cisplatin 24 h prior to simultaneous gemcitabine and FR-WB-TT. Administering cisplatin 24 h prior to gemcitabine was more effective and less toxic than giving the two drugs simultaneously or gemcitabine prior to cisplatin. Survival was greatest when gemcitabine and FR-WB-TT were administered 24 h after cisplatin, even with reduced drug doses. One complete cure resulted from the triple agent treatment.
  
  
  CONCLUSIONS
  The relative timing of agents in multiple modality treatments is critically important in achieving tumor control or cures, and in reducing toxicity. Optimizing the relative timing of multiple agents in thermochemotherapy allows use of lower drug doses to achieve maximal anti-tumor efficacy and minimal toxicity.
authors.affiliation: Division of Oncology, Department of Internal Medicine, The University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA. joan.m.bull@uth.tmc.edu
authors.forename: J M C
authors.initials: JM
authors.lastname: Bull
authors.forename: F R
authors.initials: FR
authors.lastname: Strebel
authors.forename: G N
authors.initials: GN
authors.lastname: Jenkins
authors.forename: W
authors.initials: W
authors.lastname: Deng
authors.forename: R W
authors.initials: RW
authors.lastname: Rowe
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D005260:Female; D006979:Hyperthermia, Induced / Q000379:methods*; D015674:Mammary Neoplasms, Animal / Q000473:pathology / Q000628:therapy*; D020360:Neoadjuvant Therapy / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine